Table 1.
Participant characteristics among non-Hispanic white (NHW) and black (NHB) women diagnosed with stage I-IV breast cancer between 2010 and 2014 in the Metropolitan Atlanta area (n=8,523)
| Variable | Total (N=8,523) | NHW (N=4,943) | NHB (N=3,580) |
|---|---|---|---|
| Age at diagnosis, mean (SD) | 58.4 (13.3) | 59.9 (13.3) | 56.4 (13.0) |
| Insurance, n (%) | |||
| Uninsured | 201 (2.4) | 57 (1.2) | 144 (4.0) |
| Private/military | 5,150 (60.4) | 3,140 (63.5) | 2,010 (56.1) |
| Medicaid | 655 (7.7) | 139 (2.8) | 516 (14.4) |
| Medicare | 2,389 (28.0) | 1,545 (31.3) | 844 (23.6) |
| Missing | 128 (1.5) | 62 (1.3) | 66 (1.8) |
| Poverty†, n (%) | |||
| 0–<5% | 1,740 (20.4) | 1,529 (30.9) | 211 (5.9) |
| 5–<10% | 1,924 (22.6) | 1,469 (29.7) | 455 (12.7) |
| 10–<20% | 2,617 (30.7) | 1,320 (26.7) | 1,297 (36.2) |
| 20–100% | 2,242 (26.3) | 625 (12.6) | 1,617 (45.2) |
| Stage, n (%) | |||
| I | 4,124 (48.4) | 2,727 (55.2) | 1,397 (39.0) |
| II | 2,878 (33.8) | 1,537 (31.1) | 1,341 (37.5) |
| III | 949 (11.1) | 444 (9.0) | 505 (14.1) |
| IV | 572 (6.7) | 235 (4.8) | 337 (9.4) |
| Subtype, n (%) | |||
| Luminal A | 5,585 (65.5) | 3,511 (71.0) | 2074 (57.9) |
| Luminal B | 957 (11.2) | 525 (10.6) | 432 (12.1) |
| HER2-enriched | 357 (4.2) | 172 (3.5) | 185 (5.2) |
| Triple negative | 1,047 (12.3) | 401 (8.1) | 646 (18.0) |
| Missing | 577 (6.8) | 334 (6.8) | 243 (6.8) |
| Laterality, n (%) | |||
| Right side | 4,251 (49.9) | 2,505 (50.7) | 1,746 (48.8) |
| Left side | 4,253 (49.9) | 2,431 (49.2) | 1,822 (50.9) |
| Missing | 19 (0.2) | 7 (0.1) | 12 (0.3) |
| Surgery type, n (%) | |||
| None | 872 (10.2) | 344 (7.0) | 528 (17.7) |
| bcs | 4,092 (48.0) | 2,492 (50.4) | 1,600 (44.7) |
| Mastectomy/radical | 3,555 (41.7) | 2,105 (42.6) | 1,450 (40.5) |
| Radiation, n (%) | |||
| No/discordant* | 3,342 (39.2) | 1,974 (39.9) | 1,368 (38.2) |
| Yes | 4,807 (56.4) | 2,805 (57.7) | 2,002 (55.9) |
| Missing | 374 (4.4) | 164 (3.3) | 210 (5.9) |
| Chemotherapy, n (%) | |||
| No/discordant* | 4,323 (50.7) | 2,866 (58.0) | 1,457 (40.7) |
| Yes | 3,997 (46.9) | 1,962 (39.7) | 2,035 (56.8) |
| Missing | 203 (2.4) | 115 (2.3) | 88 (2.5) |
| Hormone therapy, n (%) | |||
| No | 3,061 (35.9) | 1,590 (32.2) | 1,471 (41.1) |
| Yes | 5,151 (60.4) | 3,182 (64.4) | 1,969 (55.0) |
| Missing | 311 (3.6) | 171 (3.5) | 140 (3.9) |
| Trastuzumab, n (%) | |||
| No | 7,461 (87.5) | 4,395 (88.9) | 3,066 (85.6) |
| Yes | 1,062 (12.5) | 548 (11.1) | 514 (14.4) |
| Lymph node involvement, n (%) | |||
| Negative | 5,080 (59.6) | 3,181 (64.4) | 1,899 (53.0) |
| Positive | 2,482 (29.1) | 1,307 (26.4) | 1,175 (32.8) |
| Not examined | 961 (11.3) | 455 (9.2) | 506 (14.1) |
| Cause of death, n (%) | |||
| Alive | 6,824 (80.1) | 4,139 (84.0) | 2,685 (75.0) |
| CVD mortality | 172 (2.0) | 102 (2.1) | 70 (2.0) |
| BC mortality | 1,056 (12.4) | 434 (8.8) | 622 (17.4) |
| Other mortality | 471 (5.5) | 268 (5.4) | 203 (5.7) |
†
, percentage of census tract at or below the federal poverty line
*
, discordant therapy refers to recommendation for therapy, but not given due to patient preference or contraindication.